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Abstract
Background Esophageal adenocarcinoma carries a poor prognosis and therefore treatment of early neoplasia arising in the 
precursor condition Barrett’s esophagus (BE) is desirable. Visible lesions arising in BE need endoscopic mucosal resection 
for accurate staging and removal. Resection modalities include a cap-based system with snare and custom-made multiband 
mucosectomy (MBM) devices (Duette, Cook Medical Ltd). A new MBM device has recently become available (Captivator, 
Boston Scientific Ltd).
Objectives A retrospective pilot study to compare the efficacy, safety, specimen size and histology of endoscopic mucosal 
resection (EMR) specimens resected with two MBM devices (Cook Duette and Boston Captivator) in treatment naive patients 
undergoing endoscopic therapy for BE neoplasia.
Methods Consecutive EMR procedures carried out by a single experienced endoscopist were analysed. All visible lesions 
were marked and resected using one of the two MBM devices. All resected specimens were analysed by the same two expe-
rienced pathologists. The resected specimens in both groups were analysed for maximum diameter, minimum diameter, 
surface area and depth.
Results Twenty consecutive patients were analysed (18M + 2F; mean age 74) in the Duette group and 20 (17M + 3F; mean 
age 72) in the Captivator group. A total of 58 specimens were resected in the Duette and 63 in the Captivator group. Min 
diameter, max diameter, surface area and depth of the ER specimens resected by the Captivator device were significantly 
larger than that by the Duette device [min diameter 9.89 mm vs 9.07 mm (p = 0.019); max diameter: 13.54 mm vs 12.38 mm 
(p = 0.024); surface area: 135.40 mm2 vs 113.89 mm2 (p = 0.005); depth 3.71 mm vs 2.89 (p = 0.001)].
Conclusions These two MBM devices showed equivalent efficacy and safety outcomes, but the EMR Captivator device 
resected specimens with a larger area in the esophagus when compared with the Duette device. A possible advantage of this 
is in situations where en bloc resections with fewer EMRs are desirable for larger lesions.
Keywords Barrett’s esophagus (BE) · Esophageal adenocarcinoma (EAC) · Endoscopic mucosal resection · Multiband 
mucosectomy (MBM)
Barrett’s esophagus (BE) is a precancerous condition that 
predisposes to esophageal adenocarcinoma (EAC) and is 
characterised by a change of normal squamous epithelium 
lining the esophagus to metaplastic columnar epithelium due 
to chronic acid reflux [1]. The incidence of EAC in Western 
countries has increased in recent years and despite advances 
in surgical and oncological interventions, long-term sur-
vival remains poor. Surgical management of early esopha-
geal neoplasia carries significant mortality rates [2–4]. In 
recent years there have been significant developments in 
minimally invasive endoscopic eradication therapy (EET) of 
BE neoplasia with high eradication rates and a good safety 
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profile; therefore, there has been more emphasis on targeting 
patients at an earlier stage which can be amenable to EET 
that can improve patient outcomes. Endoscopic therapy of 
dysplastic BE and adenocarcinoma has been recommended 
by various major societal guidelines [5, 6].
Current consensus is that visible lesions arising in BE are 
removed by endoscopic resection (ER) as they may harbour 
the most advanced histological stage. Accurate staging with 
endoscopic mucosal resection (EMR) is a key step in the 
treatment of early neoplasia as it allows accurate risk stratifi-
cation of patients. Resection specimens provide information 
on depth of mucosal or submucosal invasion and presence 
or absence of lympho-vascular invasion, which subsequently 
would allow appropriate modalities of further treatment to 
be offered [7]. ER is effective and safe in selected patients 
with early BE neoplasia with significantly high (up to 94%) 
long-term complete remission rates and low major compli-
cation rates [8, 9]. The endoscopic management of early 
BE neoplasia is the preferred treatment modality as surgical 
options carry a much higher complication rate [2, 3, 10].
Historically, the cap-based system with snare (Olympus 
Ltd.), initially described in Japan by Inoue et al. [11], was 
used. This is an ER modality that uses a transparent cap 
placed distally at the tip of the endoscope. The cap con-
tains a distal internal ridge, allowing the placement of a 
snare in the cap prior to resection. The submucosal space 
is initially injected for lifting and subsequently the mucosa 
is suctioned into the cap in order to create a pseudopolyp. 
The pseudopolyp is then resected by closing the snare at the 
base of the pseudopolyp and applying electrocautery. This 
technique is a rather complicated process for the less expe-
rienced endoscopists, as it requires submucosal lifting and 
placing the snare at the distal ridge of the transparent cap 
prior to resection. This technique also results in prolonged 
procedure time in cases requiring multiple resections [12].
Cap EMR has a role in select cases but has now been 
widely replaced by the custom-made multiband mucosec-
tomy (MBM) devices that utilises a transparent cap placed 
distally at the tip of the endoscope. The cap carries multiple 
pre-loaded rubber bands that are connected to a hand-oper-
ated controller fixed at the proximal aspect of the accessory 
channel. The neoplastic mucosa is suctioned into the trans-
parent cap, followed by release of a band by the controller, 
resulting in the creation of a pseudopolyp. The contraction 
of the rubber band at the base of the pseudopolyp is only 
adequate to withhold the mucosa but not the underlying 
muscularis propria, hence the injection of the submucosal 
space is not routinely required. A snare is passed through 
the accessory channel of the endoscope and then is placed 
and closed at the base of the pseudopolyp, beneath the band. 
The pseudopolyp is then resected using electrocautery [13]. 
This is an easier method and the learning curve for MBM 
is shorter compared with that of ER cap as it combines the 
commonly known techniques of variceal band ligation and 
polypectomy [12].
The most commonly utilised MBM device is the Duette® 
Multi-Band Mucosectomy device (Cook Medical, Limerick, 
Ireland) [14]. It is a modified version of the variceal band 
ligator that allows the passage of a snare into the working 
channel of the endoscope (Fig. 1) [15]. A new MBM device 
has been launched (Captivator, Boston Scientific Ltd). This 
device also consists of a cap placed at the distal end of 
the scope with a controller placed at the proximal aspect 
of the working channel. The cap carries six rubber bands 
that are placed at the proximal aspect of the cap allowing 
360° peripheral viewing through the transparent cap with-
out obstructions by the ligator bands (Fig. 2). An in vitro 
assessment of the performance of the new EMR Captiva-
tor device by Schölvinck et al. showed that the new MBM 
device potentially allows better visualisation through the cap 
Fig. 1  Duette EMR device. The single-use Duette MBM device con-
sists of a transparent cap with six rubber bands and a control handle 
(A). The transparent cap is mounted at the tip of the endoscope. With 
a trigger cord, the six rubber bands on the outside of the transpar-
ent cap are connected to the control handle at the proximal end of the 
accessory channel. Without prior submucosal injection for lifting, the 
neoplastic lesion is delineated with the tip of the hot snare (B) and 
suctioned into the cap until a complete red out occurred on the screen 
due to the entire cap being filled with mucosa and then a pseudopolyp 
is created by releasing a rubber band (C). The pseudopolyp is then 
resected (D) by placing and tightening the snare beneath the rubber 
band
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and easier passage of accessories through the scope with 
significantly better suction power [16].
Objectives
The primary objectives of this study were to assess the effi-
cacy (defined by successful resection of all the delineated 
areas in one single session) and safety of the two MBM 
devices (Cook Duette and Boston Captivator) in treatment 
of naïve patients with BE neoplasia undergoing EMR.
Secondary objectives included retrospective compari-
son of the size of the resected EMR specimens by the two 
MBM devices in consecutive patients with BE neoplasia. 
Minimum diameter, maximum diameter, surface area and 
depth (defined as microscopically measured thickness) of 
the resected EMR specimens were compared to identify 
if either of the devices is capable of resecting larger EMR 
specimens. Final histology of EMR specimens obtained by 
the two MBM devices was also compared.
Materials and methods
Patient selection and inclusion criteria
A retrospective study looking at treatment naive patients 
(defined as those with no prior endotherapy and radio-
therapy) with BE neoplasia undergoing EMR from March 
2015 to October 2017. Consecutive patients treated by the 
Cook Duette or the Boston Captivator device in a high-
volume tertiary referral centre were analysed. Patients aged 
18–90 years with a visible lesion detected on white light 
endoscopy, narrow band imaging or optical enhancement, 
confirmed on recent endoscopy and deemed suitable for ER 
were included. Written informed consent was obtained from 
all patients prior to the procedure.
Exclusion criteria
Patients with previous esophageal EET, including EMR/
endoscopic submucosal dissection (ESD), radio frequency 
ablation, cryoablative therapy, laser treatment, photody-
namic therapy, argon plasma coagulation or radiotherapy 
were excluded from the study. In addition, patients with 
esophageal stenosis (preventing the passage of a gastro-
scope), esophageal varices and coagulopathy were also 
excluded from this study.
IRB approval was not required as this project was a ret-
rospective audit of routine clinical care and deemed exempt 
as per UK guidelines on clinical audit [17].
Endoscopic procedure
All ERs were performed by a single experienced sen-
ior endoscopist with extensive experience in EMR in the 
esophagus using both the Duette and the Captivator devices. 
The same therapeutic gastroscope with a 3.2-mm working 
channel was used.
At the time of endoscopy, the distance of the visible 
lesions (centimetre) from the incisors was recorded in addi-
tion to the location and estimated size of the lesion (millime-
tre). Lesions were classified according to the Paris classifica-
tion [18]. The length of the BE segment was also defined as 
per Prague Classification [19]. Visible lesions were deline-
ated (Fig. 1) with the tip of the device snare (ERBE VIO 
300D, Forced Coag, Effect 2, 40 W). After delineation, 
lesions were resected using one of the two MBM devices: 
Duette or Boston Captivator (Figs. 1, 2). The decision on 
which device was used was non-randomised and not con-
trolled for in the study and device selection was done at the 
outset of each case at the endoscopist’s discretion.
Immediately after the resection in both groups, the snare 
was retracted; the resected specimen was pushed into the 
stomach and the resection base was inspected. Subsequent 
Fig. 2  Captivator EMR device. The Captivator™ EMR device is a 
single-use device. The device includes the Captivator™ EMR Band 
Ligator mounted at the proximal aspect of the accessory channel and 
a banding cap device placed at the distal end of the scope for crea-
tion of pseudopolyps (A). A pseudopolyp is created by suctioning the 
neoplastic mucosa into the cap (B) until a complete red out occurred 
on the screen due to the entire cap being filled with mucosa and then 
a band is deployed using a proximally attached band ligator (C). A 
snare is then passed through the accessory channel of the scope, 
placed over the pseudopolyp and then closed beneath the rubber band 
(C), the pseudopolyp is resected (D) in conjunction with coagulation 
current. The device can be used for up to six resections
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resections were performed (if necessary) in the same way to 
cover all marked areas, with only a small overlap between 
adjacent resections to prevent residual tissue bridges. After 
completion of resection of the delineated area, the resection 
base was carefully re-inspected to ensure that all delineation 
markings have been removed.
Identical diathermy setting (ERBE VIO 300D, Forced 
Coag, Effect 2, 40 W) and suction pressures (100 kPa) were 
used in all resections. Submucosal injection and lifting of 
the mucosa was not used in any of the cases. All resected 
specimens were successfully retrieved from the stomach 
using a Roth Net® (US endoscopy, a subsidiary of STERIS 
corporation). All specimens were pinned down to cork board 
(Fig. 3) by the same endoscopy nurses and preserved in iden-
tical volumes of formalin for histological evaluation by the 
same two experienced senior GI pathologists.
The endoscopist and the endoscopy nurses were not 
blinded to the type of device used but the GI pathologists 
(performing the measurements on the specimens) were not 
aware of the devices used for the mucosal resection.
Preparation of histological specimens
EMR specimens were placed in formalin after fixation 
to a non-absorbent cork board (Fig. 3), then sectioned in 
2-mm slices and embedded in paraffin, after which 4-µm 
thick slices were cut, placed on glass slides and stained 
with haematoxylin and eosin. The dimensions of resected 
EMR specimens were measured macroscopically by the 
pathologist prior to sectioning. These included the maxi-
mum diameter and the minimum diameter (Fig. 3). The 
depth (defined as the microscopically measure thickness) 
of each EMR specimen including submucosal invasion was 
measured microscopically by the pathologist. These meas-
urements were provided on the histology report. Grading of 
intraepithelial neoplasia was in concordance with the Vienna 
classification [20]. The surface area  (mm2) of each specimen 
was then approximated by multiplying the minimum diam-
eter (millimetre) by the maximum diameter (millimetre) for 
each specimen.
Statistical analysis
Statistical analysis was performed using the SPSS Statistics 
software (Version 25). Quantitative variables were expressed 
as means (± SD) and qualitative variables were presented 
as percentages. The mean value in the two groups (Duette 
and Captivator) was compared using Student’s t test. Fish-
er’s exact test used to compare R0 and R1 between the two 
groups.
Results
The study included 20 patients in each group (Duette: 
18M + 2F; mean age 74 years; Captivator: 17M + 3F; mean 
age 72 years) with a mean length of BE of C4M6 in the 
Duette and C3M5 in the Captivator group, p = NS (Table 1). 
The endoscopically estimated mean lesion diameter was 
12 mm in the Duette and 15 mm in the Captivator group 
(p = 0.22). This estimate was carried out prior to resection 
by the endoscopist. Successful resection was achieved in 
100% of the cases with a total of 58 specimens resected in 
the Duette and 63 in the captivator group. The mean number 
Fig. 3  EMR specimen post resection. Pinned down on cork board, 
showing the maximum diameter and the minimum diameter. These 
measurements were done macroscopically by the GI pathologist
Table 1  Patient demographic and mean Prague classification for the 
Duette and the Captivator group
SD standard deviation, 95% CI 95% confidence interval
Duette Captivator t Test
Number of patients 20 (18M + 2F) 20 (17M + 3F)
Mean age 74 years 72 years p = 0.51
SD ± 9 ± 10
95% CI 70–78 67–76
Mean Prague classification
 C 4 3 p = 0.76
 Range 0–15 0–13
 M 6 5 p = 0.85
 Range 1–15 1–15
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of EMRs performed per delineated lesion was 2.6 in the 
Duette and 2.8 in the Captivator group, p = 0.67 (Table 2).
Histology
All lesions were described using the Paris classification 
prior to EMR. Paris IIa was the most common lesion seen 
(Table 3) in both groups [80% (16/20) in the Captivator and 
75% (15/20) in the Duette group; p = 0.70]. Table 3 shows 
the Paris classification of all the lesions.
Nineteen patients in the Captivator group had EMR speci-
mens with clear deep margin in comparison to 17 in the 
Duette group, p = 0.61 (Table 4). Fifteen of the patients in 
the Captivator group showed cancer on the EMR specimens 
in comparison to 12 in the Duette group (p = 0.50). Of those 
with cancer on EMR specimens, 50% showed submucosal 
involvement in the Duette group and 20% in the Captivator 
group, p = 0.13 (Table 5).
EMR specimen size comparison
The mean minimum diameter, maximum diameter, sur-
face area and depth of all resected specimens with the 
Captivator device was compared with that resected by the 
Duette device (Table 6). The data showed that the Capti-
vator EMR specimens to be significantly larger than simi-
lar specimens resected with the Duette device [minimum 
diameter 9.89  mm vs 9.07  mm (p = 0.019); maximum 
diameter: 13.54 mm vs 12.38 mm (p = 0.024); surface area: 
135.40 mm2 vs 113.89 mm2 (p = 0.005); depth 3.71 mm vs 
2.89 (p = 0.001)].
Complications
There were no reported perforations in either group. There 
was minor bleeding during the procedure that occurred in 
two (10%) patients in the Captivator group and one (5%) 
patient in the Duette group (p = NS). These were success-
fully treated with the tip of the hot snare, and there was 
no reported re-bleeding or hospitalisation. In our study, 
re-bleeding was only considered a relevant complication 
if it led to unplanned admission, endoscopic re-interven-
tion and the need for blood transfusion. There was 1 (5%) 
delayed bleed at 48 h post Captivator EMR and 1 (5%) at 
9 days post Duette EMR (p = NS). Both cases required con-
ventional endoscopic therapy that was successful on first 
attempt. Both patients had an in-patient stay of 48 h post 
endotherapy for routine observation only. First follow-up 
endoscopy (3-months post EMR) showed 1 (5%) stricture 
in both groups (p = NS) requiring one endoscopic dilatation.
Discussion
ER for visible BE neoplasia can achieve successful outcomes 
if diagnosed at an early stage [21–23]. Minimally invasive 
EET has significantly developed in the past decade and has 
shown improved mortality and morbidity in comparison to 
surgical management of early BE neoplasia [2, 3].
MBM is a widely used technique for the ER of neopla-
sia in the esophagus. MBM is effective in selected groups 
of patients [9] and it allows safe piecemeal resections in 
patients with BE neoplasia. Time and costs are saved com-
pared with the cap and snare technique [24].
This study showed that the EMR specimens resected with 
Captivator device appear to have a larger minimum diameter, 
maximum diameter, surface area and depth in the esopha-
gus when compared with the Duette device in similar treat-
ment naive BE segments. Baseline lesion morphology and 
Table 2  Total number of specimens, mean endoscopically estimated 
lesion diameter and mean number of EMR per lesion for the Duette 
and the Captivator group
SD standard deviation, 95% CI 95% confidence interval
Duette Captivator t Test
Total number of specimens 58 63
Mean endoscopically estimated 
lesion diameter (mm)
12 15 p = 0.22
 SD ± 9 ± 13
 95% CI 7–16 10–21
Mean no. of EMR per lesion 2.6 2.8 p = 0.67
 SD ± 1.6 ± 2.1
 95% CI 1.9–3.4 1.9–3.7
Table 3  Comparison of Paris 
classification of all the lesions 
in the Duette and the Captivator 
group (p = 0.70)
Paris classification Is Ip IIa IIb IIa/IIc
Captivator 2/20 (10%) 0 16/20 (80%) 1/20 (5%) 1/20 (5%)
Duette 0 1/20 (5%) 15/20 (75%) 2/20 (10%) 2/20 (10%)
Table 4  Invasion of deep margin of EMR specimens with BE neopla-
sia in the Duette and the Captivator group
R0 R1
Number of patients in the 
Captivator group
19/20 (95%) 1/20 (5%)
Number of patients in the 
Duette group
17/20 (85%) 3/20 (15%)
Fisher’s exact test p = 0.61
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subsequent resection pathology were similar in both cohorts 
of examined patients. A possible clinical advantage of this 
is in situations where en bloc resection is wanted for larger 
or more extensive lesions (> 10 mm) with fewer resections 
per lesion. This may also have a positive impact on reduc-
ing procedure time as fewer resections may be needed for 
any given lesion size and shorter procedure time is known 
to reduce the total cost of treatment [12]; however our study 
did not formally assess the procedure time between the two 
groups and we do not have data to support this notion in this 
study. In addition, fewer resections may reduce the number 
of complications such as bleeding and perforation; however, 
our study showed no significant difference between the two 
groups with regards to bleeding and there were no recorded 
perforations. This is a potential objective for future studies 
on the Captivator device. Successful resection was achieved 
in 100% of the cases which illustrates that both devices are 
very effective in this respect.
Complete resection of an extensively large lesion dur-
ing the first endotherapy session is desirable as subsequent 
strictures and fibrosis may preclude further endotherapy and 
resection. Also resecting larger areas at baseline endoscopy 
may leave less residual BE reducing the number of sessions 
for further endotherapy with ablation and the potential need 
for rescue EMR [25]. A large study by Pech et al. from 
1000 consecutive patients with IMC suggested that com-
plete removal of the whole neoplastic lesion in one session 
is favourable in order to reduce the risk of treatment failure 
[9]. This further supports the use of the Captivator device 
in patients with large lesions requiring complete successful 
resection in one session.
A previous study by Matsuzaki et al. demonstrated that 
larger ER specimens result in deeper resections [26]. Our 
study was able to show that the Captivator device resected 
specimens that had significantly larger microscopically 
measured depth in comparison to that with the Duette 
device; however, this did not result in higher perforation 
or bleeding rates, which were not significantly different, 
compared to that in the Duette group. The deep resection 
margins and radicality of neoplasia resection in our cohort 
of cases was not different in both the cancer and dyspla-
sia cases. Deeper resection may be an important factor to 
consider in patients with suspicions of submucosal inva-
sion at baseline. In these patients, for example, those that 
have significant contraindications to surgery, EET with a 
device with the potential of deeper resection capability may 
provide them with the best chance of curative endoscopic 
therapy. Larger and deeper EMR specimens also allow more 
precise evaluation of the depth of tumour penetration than 
any other available methods, which would allow differentia-
tion of mucosal from submucosal tumours [25]. Large EMR 
specimens may be able to identify patients with submucosal 
invasion suitable for escalation to surgical management and 
therefore excluded from endoscopic therapy that may result 
in a less favourable long-term outcome.
In recent years, en bloc resection with ESD in large 
lesions have become attractive in the management of patients 
with BE neoplasia [27–29]. ESD is only available in expert 
centres with highly skilled operators. The use of the EMR 
Captivator device in BE neoplasia can potentially mimic this 
for larger lesions by acquiring larger tissue specimens and 
therefore in comparison to the Duette device, it may become 
the preferred tool for larger lesions.
Both MBM devices were shown to be equally safe and 
effective at resecting visible lesions in patients with BE 
neoplasia when performed by an experienced endoscopist 
Table 5  Cancer cases with 
submucosal invasion based 
on the EMR specimens in the 
Duette and the captivator group
Cancer Mucosal cancer Submucosal cancer
Number of patients in the Captivator group 15/20 (75%) 12/15 (80%) 3/15 (20%)
Number of patients in the Duette group 12/20 (60%) 6/12 (50%) 6 /12 (50%)
 Fisher’s exact test p = 0.50 p = 0.13
Table 6  Comparing specimen size between the Duette and the Capti-
vator group
SD standard deviation, CI confidence interval
Duette group Captivator group t Test
Number of specimens 58 61
Mean min diameter 
(mm)
9.07 9.89 p = 0.019
 SD ± 1.99 ± 1.76
 Lower 95% CI of mean 8.55 9.45
 Upper 95% CI of mean 9.59 10.33
Mean max diameter 
(mm)
12.38 13.54 p = 0.024
 SD ± 2.63 ± 2.89
 Lower 95% CI of mean 11.69 12.82
 Upper 95% CI of mean 13.06 14.26
Mean surface area 
 (mm2)
113.89 135.40 p = 0.005
 SD ± 38.75 ± 42.68
 Lower 95% CI of mean 103.83 124.77
 Upper 95% CI of mean 123.95 146.02
Mean depth (mm) 2.89 3.71 p = 0.001
 SD ± 1.19 ± 1.53
 Lower 95% CI of mean 2.58 3.33
 Upper 95% CI of mean 3.20 4.09
Surgical Endoscopy 
1 3
in identical clinical environment. The intra-procedural 
acute minor bleeding episodes were considered clinically 
irrelevant because all were treated endoscopically during 
the same procedure by coagulation using the tip of the 
hot snare. The intra-procedural acute minor bleeding and 
delayed bleeding in both groups were not significantly differ-
ent. The acute and delayed bleeding rates did not reflect that 
of recently published data [22, 23]. There were no reported 
perforations. Sample size was not calculated and therefore 
the patient numbers in both groups may have been inad-
equate to show statistically significant difference in compli-
cation rates between the Captivator and the Duette group. 
We emphasise that this was a clinical audit and feasibility 
analysis that may in due course support a large-scale pow-
ered RCT. In addition, the stricture rates for both groups 
(Captivator 5%, Duette 5%; p = NS) were lower than that 
documented in major recent studies (10–37%) [22, 23]; how-
ever, one must take into account that all procedures were 
performed by the same senior endoscopist with extensive 
experience in EMR. Considering the total number of patients 
and resections performed in this study, it may be possible to 
see more accurate bleeding, perforation and stricture rates 
if the number of participants were to increase significantly 
and if endoscopists with variable range of experiences were 
to perform the procedure.
The visualisation through the Captivator cap is potentially 
better compared with the Duette cap. This is due to the posi-
tion of the bands on the Captivator cap which are placed at 
the very proximal end of the cap, allowing a clear and unob-
structed view through the transparent cap. This visualisa-
tion is further improved with each release of a rubber band. 
Improved view through the Captivator cap was based on the 
endoscopist’s experience with the devices and not formally 
assessed in our study. A formal analysis of visualisation 
through the Captivator cap was analysed by Schölvinck et al. 
that showed significantly higher overall median score for the 
visualisation with the Captivator cap [16]. The endoscopist 
also noted that the passage of accessories through the work-
ing channel of the scope was better with the Captivator 
device; however, this was not formally assessed, but again 
previously confirmed by Schölvinck et al. that showed the 
passage of accessories to be significantly easier with the 
Captivator device [16].
There are several limitations to our retrospective study. 
First, retrospective collection of data may have resulted 
in information bias and may have underestimated adverse 
events. Secondly, this study was performed by an expe-
rienced endoscopist at a high-volume tertiary referral 
centre with extensive experience in resection of large and 
complicated esophageal neoplastic lesions, which may 
have influenced the results significantly and therefore we 
may have observed different results if the procedure were 
performed by endoscopist with less experience. Third, 
EMR specimens were placed in formalin post resection, 
and then sent to the pathology lab for measurement of 
their dimensions and histological analysis. Formalin may 
have affected the size of these specimens and therefore 
the measured dimensions may have been under or overes-
timated. The specimens were not measured directly after 
the resection. Fourth, in order to create a pseudopolyp, the 
EMR cap was angulated against the esophageal wall and 
the mucosa was suctioned into the cap until a complete red 
out was visualised on the screen, prior to the deployment 
of the band. The quantity and volume of the suctioned 
mucosa into the cap is dependent on the angulation of 
the cap against the mucosa, where in the esophagus the 
resection may be taking place, and the elasticity of the tis-
sue. The angulation of the cap against the mucosa was not 
controlled for in each group. In addition, tissue elasticity 
and fibrosis can affect the volume of mucosa suctioned 
into the cap. Variable prior exposure to acid reflux and 
scarring may have altered the tissue elasticity and fibro-
sis amongst some patients, limiting the volume of tissue 
being suctioned and subsequently affecting the size of the 
resected specimens. Fifth, device selection was done at the 
outset of each case, which was non-randomised and not 
controlled for in the study and at the endoscopist’s discre-
tion. This introduces a selection bias. Finally, we measured 
the surface area of each EMR specimen by multiplying the 
minimum diameter by maximum diameter of each speci-
men. These two dimensions are not independent of each 
other and therefore the calculated surface area may have 
created an artificial endpoint.
In conclusion, our data show that both the Captivator 
and the Duette MBM Devices demonstrate excellent safety 
and efficacy to successfully resect delineated esophageal 
mucosal lesions in treatment naive patients with BE neo-
plasia. The Captivator device can resect larger specimens 
and therefore may be preferred for en bloc resections of 
larger complex esophageal lesions. This may improve pro-
cedure time by reducing the number of overall resections 
which would contribute to a reduction of total procedure 
time for piecemeal ER. Improved visualisation and pas-
sage of accessories through the working channel and com-
parable bleeding and perforation rates are features that are 
desirable by senior and trainee endoscopist. A large-scale 
randomised controlled trial to compare the two endoscopic 
devices in order to define efficacy and safety in more detail 
would confirm these findings further.
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